Generex Biotechnology Corporation

generex.com

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

LESAFFRE AND RECOMBIA BIOSCIENCES ANNOUNCES STRATEGIC PARTNERSHIP TO ADVANCE INNOVATIVE GENE EDITING TECHNOLOGY

Recombia Biosciences | November 02, 2020

news image

Recombia Biosciences announces the launch of operations in Brisbane, California. The company aims to harness its proprietary genome editing technologies to accelerate the development of yeast for sustainable production of fermented ingredients. For the next few years Recombia and Lesaffre will be joining forces in the area of yeast strain development. With its partnership with Recombia, Lesaffre is investing in major pioneering technology. The ability to generate thousands of yeast strains in pa...

Read More

Medical

ASPECT BIOSYSTEMS ANNOUNCES PARTNERSHIP WITH JDRF TO ADVANCE DEVELOPMENT OF A BIOENGINEERED TISSUE THERAPEUTIC TO TREAT TYPE 1 DIABETES

Aspect Biosystems | April 07, 2022

news image

Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The JDRF-Aspect partnership supports Aspect's focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chro...

Read More

Industrial Impact, Medical

TWIST BIOSCIENCE ANNOUNCES INTEGRATED OFFERING OF ANTIBODY DISCOVERY SERVICES

Twist Bioscience | March 10, 2023

news image

On March 9, 2023, Twist Bioscience Corporation, a leading firm providing high-quality synthetic DNA through its silicon platform, announced the launch of integrated antibody discovery services. This premium offering combines the company's synthetic libraries and AI machine learning with an in vivo immunization approach acquired through its acquisition of Abveris, also known as Twist Boston. This service provides customers with optimized, development-ready antibody candidates. ...

Read More

EDITING TECHNOLOGY TO IDENTIFY AND ADVANCE GENETIC DYSFUNCTION THERAPIES

BlueAllele | July 27, 2020

news image

BlueAllele, a biotechnology company focused on enhancing the quality and precision of gene editing systems for patients with genetic diseases, announced the launch of PALIDON™, an innovative and proprietary repair template technology.Many rare genetic diseases are caused by mutations within a single gene. However, the location of the mutation often varies for different individuals with the same disease. Conventional gene editing approaches are primarily limited to correcting small re...

Read More
news image

LESAFFRE AND RECOMBIA BIOSCIENCES ANNOUNCES STRATEGIC PARTNERSHIP TO ADVANCE INNOVATIVE GENE EDITING TECHNOLOGY

Recombia Biosciences | November 02, 2020

Recombia Biosciences announces the launch of operations in Brisbane, California. The company aims to harness its proprietary genome editing technologies to accelerate the development of yeast for sustainable production of fermented ingredients. For the next few years Recombia and Lesaffre will be joining forces in the area of yeast strain development. With its partnership with Recombia, Lesaffre is investing in major pioneering technology. The ability to generate thousands of yeast strains in pa...

Read More
news image

Medical

ASPECT BIOSYSTEMS ANNOUNCES PARTNERSHIP WITH JDRF TO ADVANCE DEVELOPMENT OF A BIOENGINEERED TISSUE THERAPEUTIC TO TREAT TYPE 1 DIABETES

Aspect Biosystems | April 07, 2022

Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The JDRF-Aspect partnership supports Aspect's focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chro...

Read More
news image

Industrial Impact, Medical

TWIST BIOSCIENCE ANNOUNCES INTEGRATED OFFERING OF ANTIBODY DISCOVERY SERVICES

Twist Bioscience | March 10, 2023

On March 9, 2023, Twist Bioscience Corporation, a leading firm providing high-quality synthetic DNA through its silicon platform, announced the launch of integrated antibody discovery services. This premium offering combines the company's synthetic libraries and AI machine learning with an in vivo immunization approach acquired through its acquisition of Abveris, also known as Twist Boston. This service provides customers with optimized, development-ready antibody candidates. ...

Read More
news image

EDITING TECHNOLOGY TO IDENTIFY AND ADVANCE GENETIC DYSFUNCTION THERAPIES

BlueAllele | July 27, 2020

BlueAllele, a biotechnology company focused on enhancing the quality and precision of gene editing systems for patients with genetic diseases, announced the launch of PALIDON™, an innovative and proprietary repair template technology.Many rare genetic diseases are caused by mutations within a single gene. However, the location of the mutation often varies for different individuals with the same disease. Conventional gene editing approaches are primarily limited to correcting small re...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us